{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:59:25Z","timestamp":1766149165486,"version":"3.48.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    High-grade neuroendocrine carcinoma (NEC) of the rectum is a rare and aggressive malignancy, with limited treatment options and a poor prognosis. We report the successful off-label use of the PARP inhibitor talazoparib in a patient with metastatic, germline\n                    <jats:italic>BRCA2<\/jats:italic>\n                    -mutated rectal NEC who had a contraindication to standard immunotherapy due to underlying autoimmune disease. A 55-year-old man with ongoing severe psoriatic arthritis presented with a two-week history of rectal pain, abdominal distention, and diarrhea. Cross-sectional imaging demonstrated a rectal mass with mesorectal lymphadenopathy and multiple liver metastases. Biopsy of the rectal lesion demonstrated a high-grade, poorly differentiated NEC with a Ki-67 proliferation index of 99%. Comprehensive tumor molecular profiling identified a pathogenic\n                    <jats:italic>BRCA2<\/jats:italic>\n                    mutation (c.5291C&amp;gt;G; p.Ser1764*, with loss of the wild-type allele), which was confirmed to be a germline alteration through germline testing. There were also biallelic inactivations of\n                    <jats:italic>APC<\/jats:italic>\n                    ,\n                    <jats:italic>TP53<\/jats:italic>\n                    , and\n                    <jats:italic>RB1<\/jats:italic>\n                    . The patient received four cycles of induction chemotherapy with carboplatin and etoposide, achieving a partial radiographic response; however, treatment was complicated by cytopenias and significant fatigue. Immunotherapy was considered inappropriate as part of his initial systemic therapy regimen or as maintenance treatment due to the severe underlying autoimmune condition. Based on the germline\n                    <jats:italic>BRCA2<\/jats:italic>\n                    -mutated (g\n                    <jats:italic>BRCA<\/jats:italic>\n                    ) status, we requested emergency approval for off-label use of talazoparib, a poly(ADP ribose) polymerase (PARP) inhibitor. At 12.5 months from initial diagnosis, including after 7.5 months on talazoparib, the patient continues to show ongoing radiographic response with excellent tolerability and no adverse effects. This case illustrates the potential role of PARP inhibitors in the management of\n                    <jats:italic>BRCA2<\/jats:italic>\n                    -mutated high-grade rectal NEC. Molecular profiling techniques may uncover actionable genetic targets in rare, aggressive cancers without standard treatment options or in patients with co-morbidities that preclude standard treatment regimens.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2025.1705579","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:56:33Z","timestamp":1766148993000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Deep and durable response to talazoparib in germline BRCA2-mutated rectal neuroendocrine carcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Milan","family":"Khealani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byoung Uk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robben","family":"Schat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1186\/s12885-019-6214-z","article-title":"Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B\/FOx regimen: an experience of multidisciplinary management in clinical practice","volume":"19","author":"Bruera","year":"2019","journal-title":"BMC Cancer."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2015.12.007","article-title":"High-grade neuroendocrine colorectal carcinomas: A retrospective study of 100 patients","volume":"15","author":"Conte","year":"2016","journal-title":"Clin Colorectal Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13014-015-0411-y","article-title":"Radiation therapy improves survival in rectal small cell cancer - Analysis of Surveillance Epidemiology and End Results (SEER) data","volume":"10","author":"Modrek","year":"2015","journal-title":"Radiat Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.11.011","article-title":"The management of extrapulmonary poorly differentiated (High-grade) neuroendocrine carcinomas","volume":"40","author":"Smith","year":"2013","journal-title":"Semin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100499","DOI":"10.1016\/j.gore.2019.100499","article-title":"Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing","volume":"30","author":"Rose","year":"2019","journal-title":"Gynecologic Oncol Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0206","article-title":"Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms","volume":"30","author":"Eads","year":"2023","journal-title":"Endocrine Related Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"New Engl J Med (NEJM)."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A phase II basket trial of dual anti\u2013CTLA-4 and anti\u2013PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/medicina60030373","article-title":"Perspectives on psoriasiform adverse events from immune checkpoint inhibitors: lessons learned from our practice","volume":"60","author":"Popa","year":"2024","journal-title":"Medicina."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2024.01.001","article-title":"Pre-existing autoimmune diseases and immune checkpoint inhibitors for cancer treatment: considerations about initiation, flares, immune-related adverse events, and cancer progression","volume":"50","author":"Sparks","year":"2024","journal-title":"Rheum Dis Clin North Am"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00064-4","article-title":"Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study","volume":"5","author":"McCarter","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2058","article-title":"Germline\u2013somatic interactions in BRCA-associated cancers: unique molecular profiles and clinical outcomes linking ATM to TP53 synthetic essentiality","volume":"31","author":"Arafa","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00091","article-title":"BRCA2 alterations in neuroendocrine\/small-cell carcinoma prostate cancer: A case series","author":"Symonds","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.7836","article-title":"Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature","volume":"15","author":"Herold","year":"2018","journal-title":"Oncol Lett"},{"key":"B16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-020-00412-3","article-title":"Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"New Engl J Med (NEJM)."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"New Engl J Med (NEJM)."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"New Engl J Med (NEJM)."},{"key":"B20","article-title":"Adjuvant olaparib for patients with BRCA1 - or BRCA2 -mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"New Engl J Med (NEJM)."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"New Engl J Med (NEJM)."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"New Engl J Med (NEJM)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41698-023-00376-x","article-title":"Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge","volume":"7","author":"Keane","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"101458","DOI":"10.1016\/j.gore.2024.101458","article-title":"Prolonged treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing","volume":"54","author":"Rose","year":"2024","journal-title":"Gynecologic Oncol Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Sci (AAAS)."},{"key":"B26","article-title":"Maintenance olaparib for germline BRCA -mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"New Engl J Med (NEJM)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","author":"Riihim\u00e4ki","year":"2016","journal-title":"Int J Cancer."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23753","article-title":"Immune checkpoint inhibitors in neuroendocrine tumors: A single institution experience with review of literature","volume":"9","author":"Chauhan","year":"2018","journal-title":"Oncotarget."},{"key":"B30","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1200\/JCO.2022.40.4","article-title":"Treatment response and clinical outcomes of neuroendocrine neoplasms treated with immune checkpoint inhibitors: A single-institution experience","volume":"40","author":"Hauser","year":"2022","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00841-0","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2458948","article-title":"Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy","volume":"21","author":"Le","year":"2025","journal-title":"Hum Vaccines Immunotherapeutics."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-024-09835-y","article-title":"Progression of low-grade neuroendocrine tumors (NET) to high-grade neoplasms harboring the NEC-like co-alteration of RB1 and TP53","volume":"35","author":"Joseph","year":"2024","journal-title":"Endocrine Pathology."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02773-w","article-title":"Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms","volume":"131","author":"Elvebakken","year":"2024","journal-title":"Br J Cancer."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41698-024-00634-6","article-title":"Phase II study of talazoparib in advanced cancers with BRCA1\/2, DNA repair, and PTEN alterations","volume":"8","author":"Piha-Paul","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s12276-021-00557-3","article-title":"Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance","volume":"53","author":"Kim","year":"2021","journal-title":"Exp Mol Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1705579\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:56:34Z","timestamp":1766148994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1705579\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":39,"alternative-id":["10.3389\/fonc.2025.1705579"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1705579","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"article-number":"1705579"}}